

Pharmaceutical Stress Testing

Predicting Drug Degradation

edited by

Steven W. Baertschi

Eli Lilly and Company

Indianapolis, Indiana, U.S.A.



Taylor & Francis

Taylor & Francis Group

Boca Raton London New York Singapore

© 2005 by Taylor & Francis Group, LLC

Opiant Exhibit 2305

Nalox-1 Pharmaceuticals, LLC v. Opiant Pharmaceuticals, Inc.

IPR2019-00685, IPR2019-00688, IPR2019-00694

Page 1

Published in 2005 by
Taylor & Francis Group
6000 Broken Sound Parkway NW, Suite 300
Boca Raton, FL 33487-2742

© 2005 by Taylor & Francis Group, LLC

No claim to original U.S. Government works
Printed in the United States of America on acid-free paper
10 9 8 7 6 5 4 3 2 1

International Standard Book Number-10: 0-8247-4021-1 (Hardcover)
International Standard Book Number-13: 978-0-8247-4021-4 (Hardcover)

This book contains information obtained from authentic and highly regarded sources. Reprinted material is quoted with permission, and sources are indicated. A wide variety of references are listed. Reasonable efforts have been made to publish reliable data and information, but the author and the publisher cannot assume responsibility for the validity of all materials or for the consequences of their use.

No part of this book may be reprinted, reproduced, transmitted, or utilized in any form by any electronic, mechanical, or other means, now known or hereafter invented, including photocopying, microfilming, and recording, or in any information storage or retrieval system, without written permission from the publishers.

For permission to photocopy or use material electronically from this work, please access www.copyright.com (<http://www.copyright.com>) or contact the Copyright Clearance Center, Inc. (CCC) 222 Rosewood Drive, Danvers, MA 01923, 978-750-8400. CCC is a not-for-profit organization that provides licenses and registration for a variety of users. For organizations that have been granted a photocopy license by the CCC, a separate system of payment has been arranged.

Trademark Notice: Product or corporate names may be trademarks or registered trademarks, and are used only for identification and explanation without intent to infringe.

Library of Congress Cataloging-in-Publication Data

Catalog record is available from the Library of Congress



Taylor & Francis Group
is the Academic Division of T&F Informa plc.

Visit the Taylor & Francis Web site at
<http://www.taylorandfrancis.com>

© 2005 by Taylor & Francis Group, LLC

Opiant Exhibit 2305
Nalox-1 Pharmaceuticals, LLC v. Opiant Pharmaceuticals, Inc.
IPR2019-00685, IPR2019-00688, IPR2019-00694
Page 2

Contents

Preface iii

Contributors xi

1. Introduction 1

Steven W. Baertschi and Dan W. Reynolds

- I. General Information/Background 1
- II. Definitions/Terms 2
- III. Historical Context 4
- IV. Regulatory Context 8
- References 9

2. Stress Testing: A Predictive Tool 13

Steven W. Baertschi and Patrick J. Jansen

- I. Introduction 13
- II. Predictive Versus Definitive 15
- III. Intrinsic Stability: Conditions Leading to Degradation 18
- IV. Intrinsic Stability: Rates of Degradation 28
- V. Intrinsic Stability: Structures of the Major Degradation Products 29
- VI. Intrinsic Stability: Pathways of Degradation 36
- VII. Interpretation of the Results of Stress Testing 39
- VIII. Summary 43
- References 44

3. Stress Testing: The Chemistry of Drug Degradation	51
<i>Steven W. Baertschi and Karen M. Alsante</i>	
I. Introduction	51
II. Degradation of Common Functional Groups	52
III. Computational Tool for Evaluating Potential Degradation Chemistry-CAMEO	126
IV. Conclusion	128
References	128
4. Stress Testing: Analytical Considerations	141
<i>Patrick J. Jansen, W. Kimmer Smith, and Steven W. Baertschi</i>	
I. Stress-Testing Conditions and Sample Preparation	141
II. Methods of Analysis	160
III. Conclusions	170
References	171
5. Stress Testing: Relation to the Development Timeline	173
<i>Steven W. Baertschi, Bernard A. Olsen, and Karen M. Alsante</i>	
I. Drug Discovery Stage (Structure–Activity Relationship and Compound Selection Stage)	174
II. Pre-Clinical/Early Phase (Pre-Clinical to Phases I/II)	175
III. “Commercialization” Stage or Late-Phase Development (Phase II/III to Regulatory Submission)	177
IV. Line-Extensions (New Formulations, New Dosage Forms, New Dosage Strengths, etc.), Older Products Already on the Market (Updating Methods, Assessing Process Changes)	178
References	179
6. Role of “Mass Balance” in Pharmaceutical Stress Testing	181
<i>Mark A. Nussbaum, Patrick J. Jansen, and Steven W. Baertschi</i>	
I. Introduction	181
II. Why Is Mass Balance Important?	182
III. How Is Mass Balance Measured and Expressed?	183
IV. Stress Testing and Mass Balance	186

V. Causes of and Approaches to Solving Mass Balance Problems 186

VI. Practical Approaches to Solving Response Factor Problems 195

VII. Response Factor Example: Nifedipine 199

VIII. Conclusions 202

References 203

7. Oxidative Susceptibility Testing 205
Giovanni Boccardi

I. Mechanistic Background 205

II. Practical Tests 213

III. Oxidation of the Most Common Organic Functional Groups 225

IV. Strategy of Oxidative Susceptibility Testing 229

References 230

8. Comparative Stress Stability Studies for Rapid Evaluation of Manufacturing Changes or Materials from Multiple Sources 235
Bernard A. Olsen and Larry A. Larew

I. Introduction 235

II. Considerations for Comparative Stress Stability Studies 237

III. Literature Examples 241

IV. Statistical Design Studies 248

V. Summary and Conclusions 256

References 256

9. Physical and Chemical Stability Considerations in the Development and Stress Testing of Freeze-Dried Pharmaceuticals 261
Steven L. Nail

I. Introduction 261

II. A Brief Description of the Freeze Drying Process 262

III. An Overview of the Physical Chemistry of Freezing and Freeze Drying 264

IV. Conclusion 288

References 288

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.